Cann Group Stock

Cann Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cann Group (CAN.AX) as of Sep 4, 2026 is 43.86 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 34.52 % — a change of 27.04% (higher).

FCF Conversion

43.86 %

YoY

27.04%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cann Group is 2026 43.86 % . FCF Conversion Rate (FCF/EBITDA) of Cann Group was 2025 34.52 % . It decreases by 27.04% higher compared to the previous year.

The Cann Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
198.03 AUD
Jan 1, 2019
300.20 AUD
Jan 1, 2020
306.90 AUD
Jan 1, 2021
147.79 AUD
Jan 1, 2022
247.84 AUD
Jan 1, 2023
76.76 AUD
Jan 1, 2024
34.52 AUD
Jan 1, 2025
43.86 AUD
The Cann Group FCF Conversion history
YEARFCF ConversionYoY
43.86 %+27.04%
34.52 %-55.02%
76.76 %-69.03%
247.84 %+67.69%
147.79 %-51.84%
306.90 %+2.23%
300.20 %+51.59%
198.03 %+91.39%
103.47 %-6.96%
111.22 %
Access this data via the Eulerpool API

Cann Group Stock analysis

What does Cann Group do? Cann Group Ltd is an Australian company specializing in the production and marketing of medical cannabis. The company was founded in 2013 and is headquartered in Melbourne. The company's history began with the founding of an independent consulting firm called AusCann Group Holdings Ltd in 2014. This firm was created to inform Australian and international investors about the opportunities and possibilities in the Australian cannabis market. In 2016, a cooperation agreement was signed between AusCann and Cann Group Ltd to advance the cultivation and production of medical cannabis products in Australia. Since then, Cann Group has continuously invested in the development and growth of the Australian medical cannabis market. The company has obtained a Good Manufacturing Practices (GMP) compliance license to ensure that all products meet the highest quality and safety standards. This includes collaborating with research institutions and state health authorities to investigate the efficacy and safety of medications. Cann Group's various business areas include the production of medical cannabis, research, product development, and marketing. The company operates a cannabis cultivation facility in Cochranes Hill, Victoria, covering an area of 20 hectares. The cultivation of cannabis is carried out under controlled conditions to ensure that all products are of the highest quality and purity. The cultivated cannabis is then used to manufacture medical products such as oils, tinctures, capsules, and sprays. Cann Group also collaborates closely with research institutions and academic institutions to study the safety and efficacy of medical cannabis. The company has partnerships with the University of Melbourne, Queensland University of Technology, and Swinburne University of Technology for research on the mechanisms of cannabis, application research, and studies on the clinical efficacy of cannabis. The business model of Cann Group is based on the sale of medical cannabis products to pharmacies and medical facilities in Australia and worldwide. The company, through its license, is one of the few companies capable of producing and exporting medical cannabis for the Australian market. In addition to exporting cannabis products to Germany, New Zealand, the UK, and other countries, the sale of cannabis products to the Australian market is the largest market for Cann Group. The company offers a variety of medical cannabis products specifically developed for various medical conditions. These include products for anxiety, nausea and vomiting, pain, seizures, and many other diseases. There are also products for palliative care, which help alleviate pain and suffering in the final stages. Overall, Cann Group Ltd has played a pioneering role in the development of the Australian medical cannabis market in recent years. The company specializes in the production of medical cannabis products that meet the highest quality standards and strict regulatory requirements. The company is committed to improving the therapeutic approach to diseases and enhancing the quality of life for patients. Cann Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cann Group stock

FCF Conversion Rate (FCF/EBITDA) of Cann Group is 43.86 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Cann Group changed from 34.52 % to 43.86 %, representing a 27.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cann Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cann Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Cann Group

All Key Metrics — Cann Group